Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.37 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4148824 | 0.86 | EGFR (0.46) | ALDH1A1MAPTEGFRERBB2L3MBTL1 | |
| SCHEMBL2991478 | 0.86 | KDM4E (0.46) | ALDH1A1MAPTL3MBTL1MEN1KMT2A | |
| SCHEMBL4155464 | 0.82 | MGAM (0.42) | L3MBTL1KDM4EATMMAT2A | |
| SCHEMBL12091770 | 0.82 | PTGER4 (0.45) | ALDH1A1MAPTHPGDNPSR1L3MBTL1 | |
| SCHEMBL2998653 | 0.82 | TDP1 (0.44) | ALDH1A1MAPTL3MBTL1MEN1KMT2A | |
| SCHEMBL2999265 | 0.81 | PLA2G10 (0.53) | MAPTMDM2CYP1A2 | |
| SCHEMBL4148027 | 0.81 | DHODH (0.41) | ALDH1A1MAPTHPGDKCNH2AOC3 | |
| SCHEMBL23024879 | 0.80 | AOC3 (0.52) | ALDH1A1MAPTHPGDNPSR1RXFP1 | |
| SCHEMBL12249842 | 0.80 | EGFR (0.39) | ALDH1A1MAPTHPGDNPSR1RXFP1 | |
| SCHEMBL12249846 | 0.78 | PTGES (0.42) | ALDH1A1MAPTHPGDNPSR1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9216966-B2 | Compounds for Alzheimer's disease | Manfredi, John (US) | 2015-12-22 | — | — | US | disclosed |
| US-9034871-B2 | Compounds for Alzheimer's disease | Manfredi, John (US) | 2015-05-19 | — | — | US | disclosed |
| EP-1809601-B1 | COMPOUNDS FOR ALZHEIMER'S DISEASE | MANFREDI JOHN (US) | 2014-09-10 | — | — | EP | disclosed |
| US-20130261118-A1 | COMPOUNDS FOR ALZHEIMER'S DISEASE | MANFREDI JOHN (US) | 2013-10-03 | — | — | US | disclosed |
| US-20120225873-A1 | COMPOUNDS FOR ALZHEIMER'S DISEASE | MYREXIS, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20090099179-A1 | COMPOUNDS FOR DISEASES AND DISORDERS | MYRIAD GENETICS, INCORPORATED (US) | 2009-04-16 | — | — | US | disclosed |
| US-20080249135-A1 | N-phenylindoles; oral dosage forms; side effect reduction | MYRIAD GENETICS, INCORPORATED (US) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261118-A1 | COMPOUNDS FOR ALZHEIMER'S DISEASE | SLC18A2, SLC18A3, NLN | ALDH1A1 2169/4885MAPT 10/4885HPGD 1761/4885 |
| US-20090099179-A1 | COMPOUNDS FOR DISEASES AND DISORDERS | CLN6, NLN, CLTC | ALDH1A1 1938/4885MAPT 657/4885HPGD 3787/4885 |
| US-20080249135-A1 | N-phenylindoles; oral dosage forms; side effect reduction | NCL, PSEN2, CCNO | ALDH1A1 2795/4885MAPT 46/4885HPGD 1568/4885 |
| US-20120225873-A1 | COMPOUNDS FOR ALZHEIMER'S DISEASE | PSEN2, CHAT, PSEN1 | ALDH1A1 1321/4885MAPT 24/4885HPGD 2955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.